Company News

Share this article:
Gilead Sciences closing two cardiovascular-focused research and development offices in Colorado. The closures stem from Gilead's acquisition of California-based CV Therapeutics, according to an Associated Press report. A spokesperson for Gilead said the company is consolidating its operations in California.

AstraZeneca partnered with Forest Laboratories for the development and commercialization of ceftaroline, an experimental antibiotic. The partnership includes markets outside of the US, Canada and Japan. Financial terms of the deal were not disclosed.   

Share this article:
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.